Basic Information
| LncRNA/CircRNA Name | NAP1L6 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | Microarray, qPCR, Western blot |
| Sample | prostate cancer tissue, cell lines (PC3, 22RV1, WPMY-1) |
| Expression Pattern | up-regulated |
| Function Description | NAP1L6 expression was upregulated in PCa tissues and cell lines (both P<0.05) compared with ANTT. Besides, high expression level of NAP1L6 promotes PCa cell proliferation, migration, and invasion (all P<0.05), and is significantly associated with larger tumor diameter, distant metastasis, and shorter survival time (all P<0.05). patients with high NAP1L6 expression level had poorer biochemical recurrence-free survival. These findings suggested that NAP1L6 might be involved in the progression of PCa by regulating INHBA through PI3KAKT-mTOR and EMT pathways. |
| Pubmed ID | 30154665 |
| Year | 2018 |
| Title | Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-? A. |
External Links
| Links for NAP1L6 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |